Evaluation of the effect of acetazolamide versus mannitol on cisplatin-induced nephrotoxicity, a pilot study

International Journal of Clinical Pharmacy
Manal El HamamsyMostafa El Haddad

Abstract

Background Cisplatin-induced nephrotoxicity still occurs despite the intensive hydration approach adapted to prevent its occurrence. Objective Evaluation of the effect of acetazolamide (ACTZ) on minimizing cisplatin-induced nephrotoxicity compared to mannitol when added to hydration regimen. Setting Nasser Institute Cancer Center (NICC), Cairo, Egypt. Method A total of 35 patients planned to receive cisplatin were divided into two groups: 20 patients received mannitol and 15 patients received ACTZ. Both groups received standard hydration measures as well for prevention of cisplatin-induced nephrotoxicity. Main outcome measure Patients' kidney function was assessed using serum creatinine, creatinine clearance and blood urea nitrogen. Kidney injury was assessed using RIFLE criteria. Patients' liver function tests and hematological parameters were also monitored. Results Patients in the mannitol group showed higher risk of developing kidney injury (30%) whereas those in the ACTZ group showed lower risk (8.9%), relative risk (RR) 0.269, 95% CI 0.108-0.815. No statistically significant difference occurred between the two groups concerning liver function tests or hematological parameters. Conclusion Use of ACTZ in addition to intensi...Continue Reading

References

Aug 1, 1979·International Journal of Radiation Oncology, Biology, Physics·D LehaneY Daskal
Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Apr 1, 1990·European Journal of Clinical Investigation·H T HeidemannG Inselmann
Jan 1, 1986·Cancer Chemotherapy and Pharmacology·M P GorenM E Horowitz
Apr 1, 1985·Naunyn-Schmiedeberg's Archives of Pharmacology·H T HeidemannR A Branch
May 1, 1981·Clinical Pharmacology and Therapeutics·K J HimmelsteinL A Sternson
Jan 20, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D Lebwohl, R Canetta
May 12, 2000·American Journal of Physiology. Renal Physiology·F ShiraishiA Agarwal
Apr 30, 2003·Cancer Chemotherapy and Pharmacology·Joseph T SantosoEdward V Hannigan
Jun 5, 2003·Expert Opinion on Pharmacotherapy·Jörg Thomas Hartmann, Hans-Peter Lipp
Aug 18, 2004·Critical Care : the Official Journal of the Critical Care Forum·Rinaldo BellomoUNKNOWN Acute Dialysis Quality Initiative workgroup
Jul 16, 2005·Pediatric Hematology and Oncology·Jairam Sastry, Stewart J Kellie
Feb 10, 2006·Integrative Cancer Therapies·Keith I Block, Charlotte Gyllenhaal
Aug 19, 2007·The American Journal of the Medical Sciences·Xin YaoKenneth Nugent
Mar 5, 2008·Cancer Chemotherapy and Pharmacology·Vincent Launay-VacherUNKNOWN European Society of Clinical Pharmacy Special Interest Group on Cancer Care
Jul 25, 2009·Clinical Pharmacology and Therapeutics·K K FilipskiA Sparreboom
Sep 24, 2011·World Journal of Gastroenterology : WJG·Hyung Hwan MoonSang Ho Lee
Nov 10, 2011·Toxins·Ronald P MillerWilliam Brian Reeves
Feb 3, 2012·The Annals of Pharmacotherapy·Katherine P MorganScott W Savage
Apr 30, 2014·The Annals of Pharmacotherapy·Katherine P MorganJared Weiss
Aug 29, 2014·BioMed Research International·Abdullah Ozkok, Charles L Edelstein
Mar 5, 2015·Asian Pacific Journal of Cancer Prevention : APJCP·Yenny PrasajaRetnosari Andrajati
Apr 26, 2017·The Oncologist·Daniel J CronaMatthew I Milowsky

❮ Previous
Next ❯

Citations

Sep 30, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Antonio RuggieroGiorgio Attinà
Aug 18, 2020·European Journal of Pharmacology·Parham HabibzadehJamshid Roozbeh
Jul 10, 2021·The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG·Brady S MoffettAyse Arikan

❮ Previous
Next ❯

Related Concepts

Related Feeds